Full Report

A record business, a halved share price

Wolters Kluwer sells subscriptions to expert knowledge — the tax rules, clinical evidence, legal precedent, and compliance data that regulated professionals cannot work without — mostly as software. FY2025 revenue was €6,125 million, 83% recurring, at a 27.5% adjusted operating margin and an 18.0% return on invested capital [1]. The operating record has rarely looked better; the shares roughly halved in the year to mid-2026. This report reconciles those two facts.

Source: FY2025 Annual Report, Financial highlights 2025 [2].

The business a cold reader needs first

The company is Dutch, listed on Euronext Amsterdam, and global in its customers: its products are used by professionals in more than 180 countries, organised into five customer-facing divisions [3]. Each division serves a different regulated profession, but the model is the same in all five: combine proprietary content and deep domain expertise with software that embeds itself in a customer's daily workflow, then charge an annual subscription to stay in that workflow.

Source: FY2025 Annual Report, Divisional summary [4].

No division dominates. Tax & Accounting (€1,660m) sells compliance and workflow software to accounting firms and corporate tax departments — its cloud platforms are the group's highest-margin and fastest-growing engine. Health (€1,596m) is anchored by UpToDate, the clinical-decision reference used at the point of care in thousands of hospitals. Financial & Corporate Compliance (€1,239m) handles corporate legal registrations, entity management, and lending compliance. Legal & Regulatory (€1,005m) is the legacy legal-and-tax publishing business, now largely digital. Corporate Performance & ESG (€625m) sells corporate financial-consolidation and ESG-reporting software, led by CCH Tagetik [5]. Geographically the weight sits in the United States: North America is 63% of revenue, Europe 29%, and Asia-Pacific and the rest of the world 8% [6].

How it makes money — and why the model is defensive

The economics rest on recurrence. Recurring revenue — subscriptions and other renewing streams — was 83% of the total in FY2025 and grew 7% organically; within the digital business, cloud software revenue grew 15% organically and now makes up 46% of software revenue [7]. Renewal rates run above 90% for most core solutions, because once a firm's tax preparers or a hospital's clinicians build their day around a platform, switching is costly and risky [8]. Management reinvests 12–13% of revenue into product development each year to keep those workflows current [9].

That recurrence is the residue of a two-decade transformation from print publisher to software and information-services company. Print is now a rounding error — a modest drag on growth — while digital and services carry the business. The result is a company whose revenue is unusually predictable for its sector, and whose incremental margins are high because the content and code are already built.

The compounding record

The reason the business commanded a premium for years is visible in six years of adjusted figures: the operating margin climbed from 24.4% to 27.5%, and return on invested capital from 12.3% to 18.0%, while diluted adjusted earnings per share rose from €3.13 to €5.29 — roughly 11% a year [10].

Source: FY2025 Annual Report, Financial highlights 2025 [11].

The underlying arithmetic is the same each year: mid-single-digit organic revenue growth — 6% in FY2025 — lifted by a steady margin gain, then compounded further by shrinking the share count. On the reported IFRS basis, FY2025 revenue rose 4% to €6,125 million, operating profit 20% to €1,735 million, and net profit 21% to €1,308 million, the last flattered by a gain on a divestment; management's adjusted figures — €1,687 million operating profit, €5.29 diluted EPS — strip such one-offs out and are the cleaner read on the trend [12]. Cash backs the earnings: adjusted free cash flow was €1,348 million at a 103% conversion ratio, and the company returned more than 120% of it to shareholders in 2025 through dividends and buybacks [13][14].

Those buybacks are large enough to reshape the balance sheet. Repurchases of €1.1 billion in 2025, on top of dividends, drove total equity down €747 million to just €798 million and lifted net debt to €4,024 million, or 2.0x EBITDA — still inside the company's stated 1.5x–2.5x policy range [15][16]. A business that returns more cash than it generates and steadily retires its own stock is the classic profile of a mature, cash-rich compounder — high returns on capital, limited need to retain earnings.

What the shares have done

In 2025 the company bought back 8.6 million of its own shares at an average price of €128.45 [17]. By early July 2026 the stock traded near €58 — below the €54.64–€144.25 range of the prior year, and less than half the level at which management was retiring stock a few months earlier. On roughly €1.3 billion of net profit, the market now values the whole company at about €12.9 billion: near ten times earnings, a multiple more typical of businesses whose growth is ending than one still compounding EPS at a double-digit rate.

Sources: 2025 buyback price — FY2025 Annual Report, Note 32 [18]; share price — Euronext Amsterdam market data, close 3 July 2026; P/E derived from €12.9bn market value against FY2025 IFRS net profit [19].

The gap between the operating record and the share price is not a company-specific stumble — guidance was reiterated as recently as the Q1 2026 trading update, and no division has broken. It is a re-rating of the multiple, and its cause is the debate that now hangs over every professional-information business: whether generative AI erodes the value of proprietary expert content, or extends it. Management's own answer is that 70% of digital revenue is already AI-powered and that its "Expert AI" — generative models grounded in Wolters Kluwer's proprietary content, with an expert in the loop — makes the subscriptions stickier, not weaker [20][21]. The market, for now, is not paying for that answer.

The evidence for durability is the 83% recurring revenue, the 90%-plus renewal rates, and the workflow lock-in that AI has not yet visibly loosened. The strongest fact against it is the price itself: a market that has watched this company for decades has cut its valuation in half, and markets do not usually do that to franchises they still believe in. What would settle the question is whether organic growth and renewal rates hold — or crack — as AI-native tools reach the professions Wolters Kluwer serves. The chapters that follow test each side of that on the evidence.

---

Expert AI

The share-price fall that opened this report is, at its core, a bet that generative AI erodes the value of Wolters Kluwer's proprietary professional content. This chapter tests that bet against the record. The evidence is that AI is so far extending the franchise rather than commoditising it: adoption is measurable and early, the moat mechanism is content plus human expert validation that a general-purpose model does not replicate, and monetisation is real but still mostly a retention-and-upsell story, not yet a cleanly separable new revenue line.

From experimentation to a branded strategy

Wolters Kluwer's AI posture has moved in three deliberate steps. In 2023 it "stepped up experimentation with large language models" across dozens of use cases [1]. In 2024 it "rolled out many GenAI features, including enhanced search, summarization, Q&A, and virtual assistants" across all divisions [2]. In 2025 it consolidated the effort under one brand — "Expert AI" — and released it into flagship products, "such as UpToDate Expert AI and CCH Axcess Intelligence" [3]. By the end of 2025, management states, "nearly 70% of our digital revenues are from AI-powered solutions" [4].

Source: FY2023 Annual Report [5]; FY2024 Annual Report [6]; FY2025 Annual Report [7].

The direct question — how the company is positioned "vis-a-vis the pure AI players" — was put to incoming CEO Stacey Caywood on the FY2025 results, and her answer names the mechanism the whole thesis turns on: "What has always differentiated our business and stood the test of time, is our high quality, proprietary content and our deep domain expertise" [8].

What "Expert AI" is — and why a general model does not copy it

Expert AI is defined as "the generative and agentic AI embedded in Wolters Kluwer solutions… Grounded in our proprietary content and supported by 'expert-in-the-loop' oversight" [9]. Two inputs make it hard to replicate. The first is content the company controls: it describes "100% proprietary content databases" and a proprietary AI-enablement platform ("FAB") built in-house by a 6,500-strong technology team [10]. The architecture layers that proprietary content and customer data on top of primary sources, then routes the output through an "expert-in-the-loop" validation step before it reaches the user [11].

The second is the expert labour behind that validation. The company co-develops these solutions with thousands of domain experts: 7,600 clinicians and 100+ editors in Health; 800+ tax analysts; 500+ in-house legal experts working with 35,000 external legal authors; plus experts in compliance and ESG [12]. This is the crux of the durability case: a foundation model can summarise text, but it does not employ 7,600 clinicians to debate and validate what the guidance should say. The company's own framing is that this validation is what "performs much better than general-purpose AI models that lack content or domain knowledge" in the high-stakes decisions its products serve [13].

That claim shows up in the retention numbers. Renewal rates "for our largest subscription-based expert solutions… remained above 90%" through 2025 — the year Expert AI launched into the base [14]. The honest caveat, carried forward from the opening chapter, is that renewal is a lagging indicator: it held above 90% before AI-native competitors reached scale in these professions, so it evidences resilience to date, not immunity.

Adoption is measurable — and early

The most useful evidence is not the strategy but the take-up, and here the disclosure is unusually concrete. UpToDate is roughly 10% of group revenue and about 99% recurring, so its AI transition is a fair test of whether customers pay for the upgrade [15]. Since the October 2025 launch, roughly 80 enterprises had signed for UpToDate Expert AI — including 30 of the top 100 enterprise customers — and about one-third of renewing individual subscribers were upgrading to the premium Pro Plus bundle [16].

UpToDate Expert AI take-up since the October 2025 launch. Source: AI Investor Teach-In, 8 Dec 2025 [17]; FY2025 results call [18].

On the results call the Health leader put the enterprise number in sharper relief: "a third of our large health system customers, together representing some 1,600 hospitals, have signed up to take Expert AI" [19]. The same passage carries the sharpest counter-fact in the chapter: those signed systems "include health systems that are piloting tools from other LLMs or medical AI vendors" [20]. The competition is not a future threat; it is already inside the installed base. Management's read is that Expert AI clears "rigorous governance process and security reviews" that a general model does not, and that clinicians rate its answers highly — but the contest for the clinical-reference workflow is live now, not deferred.

In Tax & Accounting the equivalent evidence is product breadth: six Expert AI-powered modules launched across the CCH Axcess workflow, from document intake to conversational intelligence, on the industry's only fully cloud-native suite [21]. In Legal, the acquired Libra "Legal AI Workspace" launched across four European markets, combining the AI tool with proprietary content and workflow integration — the differentiation management draws against "standalone AI assistants" is "a single platform for research, analysis, and document creation, seamlessly integrated into existing workflows and customers' data" [22].

How it becomes revenue — real, but mostly upsell for now

The gap between "customers are adopting AI" and "AI is adding revenue" is where the durability case has to be tested hardest. Management lays out four monetisation avenues, and the honest reading of the table is that the weight still sits on the left-hand column — price increases that support retention — with the discretely-monetised and consumption-based models earlier in their life.

Source: AI Investor Teach-In, 8 Dec 2025 [23].

Two concrete pricing points give the upside texture. Libra, which moves the company into a new addressable market, sells at "about 2 times the value of the content offering that we would sell to a law firm" — a genuine price uplift, not a bundled giveaway [24]. And CCH Axcess Intelligence carries "consumption tiers", while the client-collaboration tool is priced against request lists sent — "a measure of output" [25]. But the same executive is explicit that for the 2023–2024 AI features, monetisation "was more about supporting our renewal rates with price increases" [26], and consumption-based pricing is "currently being tested" [27]. The company's summary line is that "AI innovation will drive our future organic growth" [28] — a forward claim the reported numbers have not yet had time to confirm as incremental rather than defensive.

The competitive reality: a shared playbook, not a unique one

The strongest structural caution is that content-plus-AI is not proprietary to Wolters Kluwer — it is the industry's answer. Thomson Reuters, which names Wolters Kluwer among its "primary global competitors," has "introduced agentic AI into our core offerings… backed by Checkpoint's comprehensive proprietary content and deep domain expertise from our tax editors" [29]. The same combination — trusted content, human experts, agentic workflow — is being deployed by the closest peers. That argues Expert AI is table stakes to defend the franchise, and the more speculative part of the thesis is whether it also expands it. (The RELX filing indexed here is a Netherlands financing entity rather than the operating LexisNexis business, so it cannot serve as a like-for-like operating comparison; the genuine peer read comes from Thomson Reuters and from Wolters Kluwer's own disclosures.)

There is also an option the company flags on the other side of the ledger: its Supervisory Board "discussed the risks and opportunities regarding potential content licensing deals in relation to AI," while continuing to "carefully monitor potential threats and business disruption" [30]. Licensing proprietary corpora to AI developers is a potential revenue avenue that does not depend on winning the end-user interface — a hedge worth watching, and a reminder the company itself treats disruption as a live risk rather than a settled question.

The measured read

On the evidence, the derating looks more like a re-rating of fear than a verdict the operating record supports — but the case is genuinely two-sided, and what would settle it is observable. The bull's best facts are the validation moat (7,600 clinicians and expert-in-the-loop, which a general model does not reproduce), measurable early adoption (30 of the top 100 health enterprises, one-third of renewing individuals upgrading), and real price uplift where the product opens a new market (Libra at roughly 2× content pricing). The bear's best facts sit in the same disclosures: rival AI vendors are already being piloted inside Wolters Kluwer's own accounts, the same content-plus-AI playbook is available to Thomson Reuters and others, and most AI monetisation so far is retention support rather than a cleanly incremental line, with consumption pricing still in test.

What would change the read, in either direction, is checkable in the filings to come: whether cloud and expert-solutions organic growth accelerates as Expert AI scales (the company's "drives future organic growth" claim made good), whether renewal rates hold above 90% as AI-native competitors mature, and whether the discretely-monetised and consumption-based avenues grow from a footnote into a disclosed contributor. Those line items — not the AI narrative — are where the durability question gets answered.

---

Ten Times Earnings

Wolters Kluwer produced record numbers in 2025 — €6,125m revenue, a 27.5% adjusted operating margin, 18.0% ROIC and €1,348m of adjusted free cash flow — yet the shares trade near €58, roughly ten times earnings and a ~10.5% free-cash-flow yield [1]. At that price the arithmetic embeds free cash flow that stays flat to modestly declining forever — a valuation that prices the durability question, not the operating result.

What the multiple is

The starting point is what the market pays today, and against what. On FY2025 diluted adjusted EPS of €5.29 the shares sit at roughly 10.9x; on the €5.63 consensus estimate for 2026 they are near 10.2x, and on the €6.23 penciled in for 2027, about 9.2x [2]. Adjusted free cash flow of €1,348m against a ~€12.9bn market capitalisation is a 10.5% cash yield. Enterprise value of roughly €16.9bn — equity plus €4,024m of net debt — is about 7.6x EBITDA on market data [3].

Sources: FY2025 adjusted FCF €1,348m and net debt €4,024m per the FY2025 Annual Report [4] [5]; price, EV/EBITDA multiple, and the ~€100 consensus 12-month target are market data, early July 2026.

Two comparisons frame how unusual this is. The first is the company against its own recent past: Wolters Kluwer carried a trailing P/E near 34x at the end of 2024 and averaged roughly 26x over the prior five years, so the ~10.6x it closed 2025 at is a de-rating of about 60% versus its own norm — a re-rating of the multiple far more than a change in the numbers. The second is against the professional-information peers management competes with directly.

Source: forward P/E from aggregated market data, late June–early July 2026; multiples are unitless. Peer identities (RELX, Thomson Reuters, Verisk) per the corpus peer set; each runs a content-plus-analytics subscription model comparable to WKL's.

RELX and Thomson Reuters — the head-to-head rivals in legal and tax whose model most closely mirrors WKL's — trade at roughly 16–19x forward earnings; Verisk, a data-analytics peer, nearer 24x. Wolters Kluwer sits about 40–55% below that band. The gap is the market's price for a single proposition: that generative AI erodes the value of WKL's proprietary expert content faster, or more certainly, than it erodes the peers'. That is the same durability question the report is built around, expressed as a discount rather than an argument.

The "record" year, cleaned up

Before pricing the future it is worth separating the headline from the run-rate, because a skeptic will. IFRS diluted EPS of €5.64 rose 25% in 2025, but that figure is flattered by items management strips out; adjusted net profit was €1,225m and diluted adjusted EPS €5.29, up 6% as reported and 9% in constant currency after a 3% reduction in the share count to 231.8 million [6]. The underlying earnings power compounded at high single digits, not 25%. The valuation work below uses the adjusted line, which is the cleaner base for what recurs.

What ten times implies

A cash-generative subscription business worth ten times earnings and yielding 10.5% on free cash flow is priced for very little growth. Treating the market capitalisation as the present value of a growing perpetuity — value equals next year's free cash flow divided by the discount rate less the growth rate — and solving backwards for the growth the price embeds:

Source: derived from FY2025 adjusted FCF €1,348m [7] and ~€12.9bn market capitalisation (market data); free-cash-flow CAGR computed from reported cash flow, 2016 (€703m) to 2025.

At an 8.5–9% cost of equity — reasonable for a business with 83% recurring revenue [8] — the current price implies free cash flow shrinks by roughly 1–2% a year in perpetuity. That is not slower growth; it is decline. Set against a free-cash-flow record that compounded at 7.6% annually from €703m in 2016 to €1,365m in 2025, and 2026 guidance for another year of good organic growth, high-single-digit adjusted-EPS growth and a margin rising toward 28% [9], the price requires the decade-long algorithm not merely to fade but to invert.

The same point read forward: re-rating to RELX's ~16x on an unchanged €5.29 of adjusted earnings would put the shares near €85, about 47% above today; a return to WKL's own five-year-average multiple would imply a figure roughly twice the current price. The consensus 12-month target of about €100 sits inside that range, which is the sell side signalling it views the de-rating as overdone — though targets lag price and have been cut as the shares fell.

The case is most sensitive to the exit multiple

Because near-term earnings are relatively well-anchored — management guides to high-single-digit adjusted-EPS growth [10] and 83% of revenue renews above 90% [11] — the outcome over two to three years turns far more on the multiple the market is willing to pay than on the exact earnings path. The multiple is where the AI-durability question gets settled.

Source: illustrative scenarios by the author. EPS anchored on FY2026–27 consensus (€5.63 / €6.23) flexed for organic-growth outcomes; exit multiples span from below today's 10x to a discount to RELX's ~16x. Current price ~€57.6 (market data).

The span is instructive. Holding earnings at a base-case €6.2, moving the exit multiple from 9x to 14x to 18x runs the price from about €56 to €87 to €112 — a ±50% swing that dwarfs the effect of the earnings flex within each column. In a bear world where AI genuinely commoditises the content, low single-digit growth and a multiple stuck near today's leaves the shares roughly flat to down; in a base case where renewals hold and Expert AI defends the franchise, a partial re-rating to a still-discounted 14x delivers the bulk of the consensus upside without heroic assumptions; only the bull case needs organic growth to inflect up.

What cuts the other way

The discount is not pure fear, and three facts argue the market has some reason. First, the balance sheet is thinner than the compounding headline suggests: total equity fell €747m to €798m in 2025 as buybacks and dividends ran above free cash flow, and net debt rose to €4,024m, or 2.0x EBITDA — the upper half of the company's own 1.5x–2.5x policy band [12] [13]. A business returning more than its free cash flow at 2.0x leverage has less room to absorb a growth disappointment than one at half the gearing. Second, the record IFRS EPS overstates the run-rate, as the adjusted line shows. Third, external analysts have shortened the duration they are willing to underwrite for these franchises — one major research house cut its explicit forecast horizon for Wolters Kluwer from twenty years to fifteen and downgraded its moat assessment, which mechanically lowers a fair-value estimate regardless of any single year's result. A ten-times multiple is cheap against history; it is less obviously cheap against a genuinely shortened franchise life.

What would move the read is specific and dated. The half-year 2026 results on 5 August 2026 carry the first clean organic-growth print since Expert AI began scaling: recurring and cloud organic growth accelerating would evidence a base-or-better case and argue the multiple is wrong; the same lines decelerating, or any softening of the 90%-plus renewal rate, would give the bear-case decline the market is pricing its first real support. Absent that, the position is a wide gap between a ten-times price and a mid-teens-and-above peer group, with the AI-durability question — tested in Expert AI — as the variable that closes it in either direction.

---

Buyback Engine

For four years Wolters Kluwer returned more than its free cash flow to shareholders, retiring €4.5 billion of stock and lifting per-share earnings faster than profit. That machine ran on the balance sheet: shareholders' equity fell from €2.3 billion to €798 million while net debt climbed to 2.0x EBITDA. For 2026 the buyback is halved to €500 million and cash reinvested into product development — a deliberate step back from the formula, taken at the lowest share price in years.

Returning more than it earned

Across 2022–2025 Wolters Kluwer paid out between roughly 117% and 126% of adjusted free cash flow every year, funding the excess with debt. In 2025 it returned €1.66 billion — €1.1 billion of buybacks plus €563 million of dividends — against €1,348 million of adjusted free cash flow, or about 123% [1] [2].

Source: FY2025 Annual Report — returns and cash conversion p.39 [3]; five-year buyback record p.229 [4].

The buyback has been a standing programme, roughly €1 billion a year, not an opportunistic one. Over 2021–2025 the company spent €4.51 billion to retire 39.1 million shares — about 13% of the count — at an average of €115.35 [5].

Source: FY2025 Annual Report, Share repurchases, cancelations, and issuances 2021–2025 [6].

Paid for out of equity

The returns came from a balance sheet that had room to give and used it. Shareholders' equity fell from €2,310 million at the end of 2022 to €1,749 million in 2023, €1,545 million in 2024, and €798 million in 2025 — a €747 million drop in the final year alone, driven by the buyback and dividends [7] [8]. Over the same window net debt rose from €2,253 million to €4,024 million, lifting net-debt-to-EBITDA from 1.3x to 2.0x [9] [10].

Source: FY2025 Annual Report balance sheet p.42 [11]; FY2024 Annual Report p.40 [12]; FY2023 Annual Report p.41 [13].

Thin book equity overstates the strain. Much of the €798 million figure is an artifact of buying back goodwill-funded shares above their carrying value: each repurchase is charged straight against equity, so a company that returns more than it earns will grind its book value toward zero regardless of how the business performs. The economic anchor is cash, not book capital — €1,348 million of adjusted free cash flow at 103% cash conversion, on 83% recurring revenue [14]. And 2.0x leverage sits inside the stated 1.5x–2.5x policy range, which the company notes has held between 1.3x and 2.4x since 2011 [15]. The constraint is real but not distress: net debt has doubled in three years, and 2.0x is the top half of the range rather than a breach.

What the buyback bought, and at what price

The mechanical payoff is visible in per-share earnings. Diluted adjusted EPS rose 9% in constant currencies in 2025, of which about a third came not from profit but from a 3% reduction in the diluted share count, to 231.8 million [16]. Repeated over a decade, that share-count shrinkage is a meaningful slice of the double-digit EPS compounding the equity story leans on (Compounder Repriced).

The price paid is the harder part. The average repurchase price climbed with the shares — €82.62 in 2021, €98.75, €114.44, then €149.23 in 2024 and €128.45 in 2025 — so the heaviest euro-spend went in near the top [17]. At €57.62 in early July 2026, the 39.1 million shares bought for €4.51 billion are worth about €2.27 billion. That is not a profit-and-loss loss — a buyback is a transfer to the sellers, not a mark-to-market position — but it is the record of a formulaic programme that could not, and did not, time the stock. Wolters Kluwer's own market capitalisation fell from €38.3 billion to €20.5 billion over 2025 [18].

One fact cuts the other way, and management makes it explicitly. As the shares fell in the second half of 2025, it accelerated the programme — completing the 2025 buyback two months early and pulling roughly €200 million of the 2026 plan forward into late 2025 "in light of the share price development" [19]. So the company leaned into weakness rather than away from it. The critique is not that it bought high on purpose, but that a standing €1-billion programme, by construction, deploys most capital when the price and the multiple are highest.

The 2026 step back

The 2026 plan is where the formula visibly bends. The intended buyback is cut to "up to €500 million," half of 2025's €1.1 billion, while annual product-development spending is lifted from 11% of revenue (about €650 million) to 12–13% "in 2026 and beyond" to fund the AI response [20] [21]. The dividend is untouched and still progressive: the 2025 total rises 8% to €2.52 per share [22]. The stated order of claims on cash is explicit — dividend first, then organic investment, then selective acquisitions, with the buyback the residual [23].

The arithmetic of the pivot: with 2026 adjusted free cash flow guided to €1,300–1,350 million, a €500 million buyback plus a dividend near €580 million takes total returns to roughly 82% of free cash flow — below 100% for the first time in years, letting leverage drift back down as EBITDA grows [24].

Sources: buybacks and cash conversion, FY2025 Annual Report pp.39, 201, 229 [25] [26]; 2026 free-cash-flow and buyback guidance p.15 [27]. 2026 returns estimated (€500m buyback plus dividend held on the progressive policy); earlier years are cash dividends paid plus buyback consideration.

Guidance for 2026 is another year of good organic growth, margin rising toward 28.0%, and high-single-digit diluted-adjusted-EPS growth in constant currencies — a step down from the 9–11% range of recent years, consistent with a smaller buyback contribution [28]. The EPS algorithm is being rebalanced from financial engineering toward reinvestment, not abandoned.

The read

The capital-return record is disciplined in design and procyclical in outcome. A standing programme retired 13% of the shares and added a third of recent EPS growth, but deployed €4.5 billion at an average price now roughly double the market, and it is being throttled just as the stock reaches its cheapest multiple in years (Ten Times Earnings). The strongest fact against reading the cut as a misstep is that management accelerated buybacks into the 2025 decline and has kept 2.0x leverage inside a policy band it has respected for over a decade — this is a reallocation, not a retreat forced by stress.

What separates prudence from error is whether the reinvestment earns its keep. Buying back stock at €57.62 is a high-return use of cash — the shares carry a free-cash-flow yield above 10% (Ten Times Earnings) — so steering roughly €600 million a year of incremental buyback capacity and product-development spend into the AI build only adds value if that spend lifts organic growth above where the maintained-buyback path would have left it. The first clean read on whether it is working comes with the H1-2026 results on 5 August 2026; until then the reallocation is a claim, not a result.

One alignment note supports management's framing rather than undercutting it: the 2023–2025 long-term incentive plan paid out below target, including a zero payout on the relative-total-shareholder-return measure, because the share-price collapse dragged Wolters Kluwer to fifteenth among its TSR peer group [29]. The people steering capital allocation felt the derating in their own pay.

---

Where the margin is earned

Wolters Kluwer's 27.5% group adjusted operating margin is earned unevenly. Three divisions — Tax & Accounting and Financial & Corporate Compliance (both about 35%) and Health (32%) — produce roughly 87% of divisional profit on about 73% of revenue, and they drove all of 2025's margin gain. Legal & Regulatory (18%) is climbing underneath a one-off; Corporate Performance & ESG (7.5%) is the one division whose margin is falling, on a cloud-transition mix shift. The group's compounding math rests on the top three.

Source: FY2025 Annual Report, Divisional Summary [1]; top-3 profit share derived from divisional adjusted operating profit [2].

The ladder

Wolters Kluwer reports five customer-facing divisions, and their profitability spans a wide band. On the FY2025 adjusted operating margin, Tax & Accounting and Financial & Corporate Compliance sit level at 35.2% [3][4], Health earns 32.1% [5], Legal & Regulatory 18.2% [6], and Corporate Performance & ESG just 7.5% [7]. The group blend is 27.5% [8].

Source: FY2025 Annual Report, Divisional Summary; FY2024 shown on the restated basis that moved Finance, Risk & Regulatory Reporting into FCC [9].

This spread is the reason a group-level margin path — the number the rest of this report leans on — can mislead. The 27.5% is not a property of "Wolters Kluwer"; it is a weighted average of one 35% software-and-compliance engine, one 32% clinical franchise, and two divisions that earn well below the group. Which divisions grow, and which ones expand margin, matters more than the headline moving 40 basis points.

Where the profit actually sits

Revenue share and profit share are not the same picture. Tax & Accounting is 27.1% of revenue but 33.1% of divisional profit; Financial & Corporate Compliance turns 20.2% of revenue into 24.8% of profit. At the other end, Corporate Performance & ESG is 10.2% of revenue but only 2.7% of profit, and Legal & Regulatory is 16.4% of revenue for 10.4% of profit [10].

Source: FY2025 Annual Report, Divisional Summary; profit shares computed against €1,764m of divisional adjusted operating profit, before €77m of unallocated corporate costs [11].

Stated plainly: Tax & Accounting, Health and Financial & Corporate Compliance together generate about 87% of the group's divisional profit. Legal & Regulatory and Corporate Performance & ESG, a quarter of revenue between them, contribute about 13%. A reader modelling the group's earnings is, to a first approximation, modelling three divisions.

Source: derived from FY2025 Divisional Summary revenues and adjusted operating profit [12].

What moved in 2025, and what only looked like it moved

The group margin rose 40 basis points in 2025, and management attributes the gain to Tax & Accounting and Health specifically [13]. Tax & Accounting added roughly 200 basis points (33.2% to 35.2%) and Health about 180 (30.3% to 32.1%) [14]. The expansion is coming from the divisions that were already the most profitable — operating leverage widening an existing lead rather than the laggards catching up.

Two of the year's apparent margin declines are artifacts rather than deterioration. Legal & Regulatory slipped from 18.6% to 18.2%, but management ties that to the absence of a 2024 one-time pension gain, "which was, to a large extent, compensated by strong underlying margin improvement" [15]. Financial & Corporate Compliance shows 35.3% in 2024 against a figure the prior year's report put near 39%; the gap is a reclassification, discussed below, not a fall in profitability. Read against a longer run, three divisions have been climbing steadily.

Source: FY2023 Annual Report, Divisional Summary (FY2022–FY2023) [16]; FY2025 Annual Report, Divisional Summary (FY2024–FY2025) [17].

Legal & Regulatory is the quiet improver: its margin has risen from 14.5% in 2022 to 18.2%, a nearly four-point climb as the division shifts from legal information toward software (Legal & Regulatory Software is now about a quarter of the division) and integrates AI-embedded research and the Libra and Brightflag acquisitions [18]. It remains the lowest-margin franchise of the three information-led businesses, but its direction is up.

The one division going the other way

Corporate Performance & ESG is the exception, and the only division whose margin is genuinely falling. Adjusted operating profit dropped 23% in 2025 (down 17% in constant currency) and the margin fell from 10.2% to 7.5%, even as revenue grew 7% organically — one of the fastest growth rates in the group [19]. Management's explanation is a mix shift, not lost demand: "The adjusted operating margin declined, reflecting the decline in licenses and a higher proportion of services provided by third parties" [20]. High-margin on-premise license fees are running off as customers move to subscription cloud — recurring cloud revenue in the division grew 18% — and the transition compresses margin on the way through even while it grows the recurring base [21].

The same page notes a second-order concern: demand for EHS platforms (the Enablon suite) remains strong, but "momentum for ESG reporting tools has slowed" [22]. CP&ESG is small enough — under 3% of divisional profit — that its margin swing barely moves the group. But it is the one place where the cloud-transition J-curve is visibly compressing margin today, and it is worth watching as a template for the larger divisions as they push cloud and AI.

The FRR reclassification and divestment

Financial & Corporate Compliance's margin needs one adjustment to read cleanly. During 2025 the company moved its Finance, Risk & Regulatory Reporting (FRR) business unit out of Corporate Performance & ESG and into Financial & Corporate Compliance, and restated the comparatives [23]. FRR carried roughly €123m of revenue at close to breakeven, so folding it into FCC diluted that division's reported 2024 margin from about 39% to 35.3% without changing a euro of its profit. FCC's underlying software-and-compliance margin is therefore closer to the high-30s than the headline 35.2% suggests.

FRR was then divested on 1 December 2025, producing a €232m gain that lifted FCC's IFRS operating profit to €625m against adjusted operating profit of €437m [24]. Two implications follow. First, the adjusted line is again the one to trust here — FCC's headline IFRS profit jumped 57%, almost entirely on a one-off, exactly the IFRS-versus-adjusted gap that Ten Times Earnings flagged at the group level. Second, removing a breakeven unit is modestly accretive to FCC's go-forward margin: the division that remains is a higher-quality business than the reported 2025 average.

Why the concentration matters to the thesis

The report's compounding case assumes the group margin keeps rising — guidance is for approximately 28.0% in 2026, up from 27.5%, while product-development spending steps up to 12–13% of revenue to fund the AI push [25]. The divisional picture shows where that has to come from. The margin gains of 2025 came from Tax & Accounting and Health, and those are precisely the divisions where Expert AI is monetising — CCH Axcess in tax, UpToDate in clinical reference (Expert AI). Management frames the reinvestment as self-funding: it will "increase our investments to deliver more AI solutions while also increasing operating margins" [26]. That is achievable only if the high-margin franchises keep widening their lead fast enough to absorb the spend and carry the two laggards.

The evidence supports the read that the margin engine is concentrated but genuinely strengthening: two divisions at 35%, both improving or stable underneath one-offs, and Health inflecting up 180 basis points in a single year. The main fact against it is the same concentration — with about 87% of profit in three divisions and no margin cushion from the other two, a stumble in Tax & Accounting or Health has little to offset it, and CP&ESG is a working demonstration that a cloud transition can pull a growing division's margin down for several years. What would change the read is the next divisional print: if the 12–13% product-development step-up lands as a margin dip in Tax & Accounting or Health rather than a continued climb, the group path to 28% loses the two engines it depends on. That is the first thing to check when the next results land.

---

Leadership Handover

Wolters Kluwer is changing chief executive for the first time since 2003, just as it halves the buyback to fund a step-up in AI reinvestment. The successor, Stacey Caywood, is an insider who ran the division that built the flagship AI product; the CFO stays; the transition ran nine months. The delivery record behind the guidance is strong — 2024 and 2025 both beaten. But the incentive plan itself now targets a lower, high-single-digit earnings bar, and the incoming CEO's own alignment is still nascent.

The question this report turns on is whether the decade formula survives the AI transition. This chapter is about who now steers it, and how they are paid to.

The first handover in twenty-two years

Nancy McKinstry led Wolters Kluwer from September 2003 to February 2026, a tenure of more than twenty-two years across which the company was rebuilt from a print publisher into a software and expert-solutions group [1]. Her successor, Stacey Caywood, becomes CEO and Chair of the Executive Board — the same combined role McKinstry held under the Dutch two-tier structure, where a separate Supervisory Board oversees management [2].

Two features make this less of a break than a first change in over two decades might imply. Caywood is an insider: her in-flight long-term incentive grants were awarded while she was CEO of the Health division [3], the division that houses UpToDate Expert AI — the single most-cited proof point in the AI-durability case (Expert AI). The architect of the flagship AI product is taking the top job. And the transition was deliberate rather than abrupt: Caywood was appointed to the Executive Board at the May 2025 AGM, then led the annual strategic-planning process for the months before taking the helm [4]. CFO Kevin Entricken, in the role since 2013, stays on, holding continuity on the capital-allocation and guidance framework the rest of this report leans on [5].

The timing is what concentrates the risk. The first CEO change in twenty-two years lands in the same year the company halves its buyback to €500m, lifts product-development spend to 12–13% of revenue, and trades at the lowest multiple in its listed history (Buyback Engine). New leadership, a reinvestment pivot, and a derating arrive together.

A record of doing what it said

The reason the 2026 algorithm — margin still rising while product-development spend steps up — carries any credibility is that management has hit its numbers. In both of the last two years it guided conservatively and delivered at or above the top of the range.

Sources: FY2025 guidance from Full-Year 2024 Results [6]; FY2024 guidance from Full-Year 2023 Results [7]; 2025 actuals from the FY2025 Annual Report remuneration report [8].

The pattern is consistent: margin above the guided range both years, free cash flow above the range both years, and adjusted EPS growth ahead of an opening guide that was framed as single-digit. In 2025 the outperformance was formalised — management raised the EPS guidance mid-year before delivering +9% in constant currencies [9]. Against the 2025 short-term-incentive targets, revenue landed at €6,125m against a €6,160m target, adjusted net profit at €1,225m against €1,204m, and adjusted free cash flow at €1,348m against a €1,225m target [10]. Adjusted operating margin has now risen every year from 25.3% in 2021 to 27.5% in 2025 [11]. The caveat that matters: this is the departing CEO's record. The 2026 plan is the first the incoming team owns outright.

Pay that moved with the shares

Management's incentive plan is not a rubber stamp. Over 2023–2025 the long-term plan paid below target across all three measures, and on relative total shareholder return it paid nothing at all: Wolters Kluwer ranked fifteenth of sixteen peers, which under the plan's rules is a zero payout [12]. The earnings and returns legs paid 98% and 77% of target respectively; the share-price leg paid zero [13].

Source: FY2025 Annual Report, Remuneration at a Glance, three-year 2023–2025 total shareholder return chart [14].

The share-price fall reached the executives' own pockets. The CEO's realised pay mix inverted: long-term incentives, weighted at 57% of target pay, delivered only 30% of realised pay once the plan was valued at the lower share price [15]. McKinstry's total 2025 remuneration fell 1.9% to €8.5m and the CEO pay ratio dropped to 66 from 77 [16]. And the alignment runs through personal holdings: McKinstry held 460,412 shares at year-end, worth 26.2 times her base salary, down from 44.2 times a year earlier as the stock fell [17].

Sources: LTIP TSR outcome and rank, FY2025 Annual Report [18]; pay ratio and total pay, Five-Year Overview [19].

The point is not that management is underpaid — €8.5m for the CEO is a large number. It is that the plan actually docked pay when shareholders lost money, which is the property an investor most wants to see and does not always get. The offsetting fact: this alignment is concentrated in the person leaving. Caywood held 18,775 shares at year-end, 1.7 times her base salary, and has five years to reach the required multiple [20]. The twenty-two-year owner-operator's stake walks out the door; the incoming CEO's is still being built.

The incentive plan's new setting

For the 2026–2028 cycle the Supervisory Board reweighted the long-term plan, lifting adjusted EPS to 50% of the award from 30%, holding relative TSR at 30%, and keeping ROIC at 20% [21]. Earnings growth is now the largest single lever in management's own pay. What that lever is set to reward is the notable part.

Source: FY2025 Annual Report — delivered CAGR from the LTIP 2023–2025 outcome [22]; forward targets from the prospective LTIP disclosure [23].

The EPS growth target for 2026–2028 is a compound 9.1% in constant currencies, with the 2025–2027 cycle set at 8.4% [24]. Both sit below the 10.5% the company actually delivered over 2023–2025 [25] and below the roughly 11% adjusted-EPS compounding the decade record established (Compounder Repriced). The pay plan, in other words, formalises the deceleration the 2026 guidance already signalled: Caywood's own outlook is for high-single-digit adjusted-EPS growth while product-development spend rises to 12–13% of revenue and margin still expands [26]. Management is being paid more heavily on an earnings bar it has deliberately lowered. The reweighting cuts the other way too: with the buyback halved, the per-share tailwind that helped clear past EPS targets is smaller, so a 9.1% bar with less buyback support is not obviously softer than a 10% bar with a full one.

Two smaller reads sit alongside. The relative-TSR target is demanding on its own recent form: the plan asks for a position of 5–6 in the peer group [27] against the fifteenth the company just delivered — a high bar that keeps the share-price leg from being easy money. And the governance terms are shareholder-friendly: Caywood and Entricken hold four-year appointments with severance capped at one year's base salary, though a change of control triggers full vesting of conditional share rights — a clause worth noting given the compressed valuation [28]. The remuneration framework itself carries broad owner support: the policy was adopted with more than 95% of votes and the prior year's remuneration report with over 92% [29]. Oversight is being refreshed alongside management: the Supervisory Board has turned over materially, with five of its members appointed in 2022 or later [30].

Where this leaves the reader

On the evidence, the continuity case is the stronger one. The successor is the insider who built the flagship AI product, the CFO stays, the transition ran nine months, the delivery record is real, and the incentive plan demonstrably bites when shareholders lose money. The risks are equally real but narrower: the first leadership change in twenty-two years coincides with the reinvestment pivot and the derating; the departing CEO's large personal stake is not yet matched by the incoming one; and the pay plan now rewards a high-single-digit earnings bar rather than the double-digit compounding the multiple was built on.

What would move the read is a datapoint, not an argument. The half-year results due 5 August 2026 are the first clean print under Caywood, and the test is specific: whether the margin the whole report assumes holds in Tax & Accounting and Health while product-development spend steps up (Margin Ladder), and whether the reallocation from buyback to reinvestment shows up as organic growth rather than only as a lower share count. Delivered, it confirms the algorithm has survived the handover. Missed under new leadership, in the first year the plan is theirs, it would tell the market the formula bent at exactly the point the people running it changed.

---

Peer Benchmark

Wolters Kluwer competes head-to-head with a small cohort of professional-information compounders — RELX, Thomson Reuters, Verisk, and in tax and accounting, Intuit. On the economics that define the moat — a ~28% operating margin, cash conversion above net income, renewal rates above 90% — WKL belongs among them. It is the cohort's growth laggard: 6% organic against RELX's 7% and Thomson Reuters' 8%, and in Legal, where the three meet directly, WKL grew 5% while both rivals accelerated to 9%. At ~10x earnings versus 20–37x for the group, the discount tracks that growth gap, not weaker economics.

The cohort

The peers here are not a market-cap screen; they are the companies WKL meets in the field. Thomson Reuters names them itself: in its FY2025 filing, the Legal Professionals segment's "primary global competitors are LexisNexis (which is owned by RELX Group) and Wolters Kluwer" [1], and its Tax, Audit & Accounting segment competitors "include Wolters Kluwer's CCH business, Bloomberg Industry Group, Intuit, Drake Software, and CaseWare" [2]. WKL competes with LexisNexis and Elsevier (RELX) in Legal and Health, with Westlaw and UltraTax (Thomson Reuters) in Legal and Tax, and with Intuit's ProConnect suite in practitioner tax. WKL's own remuneration peer group, chosen to benchmark pay against comparable businesses, lists Intuit, Thomson Reuters, Verisk Analytics, RELX, and The Sage Group [3] — the same names.

A caution on the source set: the RELX and Sage documents indexed here are financing and treasury subsidiaries (RELX Finance B.V., Sage Treasury Company Limited), not the operating groups. The operating economics below therefore come from each group's reported financials and results calls, not those filings.

Where the economics land

On the structural markers of a wide moat, WKL sits squarely inside the cluster rather than below it.

Source: operating margin and FCF/net income derived from each group's latest reported financials; trailing P/E is latest close divided by reported diluted EPS (WKL €57.62 ÷ €5.64). WKL adjusted operating margin was 27.5% on 2025 revenue [4]. Vertex omitted (near-breakeven on a statutory basis).

WKL's 28.3% statutory operating margin (27.5% adjusted) is mid-pack: below Verisk's 43.7% and RELX's 31.1%, above Thomson Reuters, Intuit, and Sage on the same reported basis [5]. Free cash flow exceeds net income across every name, WKL included at ~104% — the signature of subscription businesses with negative working capital and light capital intensity. Renewal rates for WKL's largest subscription products "remained above 90%" in 2025 [6], the same retention band RELX and Thomson Reuters describe for their embedded platforms.

Two caveats keep this honest. Return on capital, which looks highest for WKL, RELX, and Verisk (all above 31%), is inflated for those three by buyback-thinned equity and depressed for Thomson Reuters and Intuit by acquisition goodwill; it is a poor cross-company moat gauge here, so the table leads with margin and cash conversion instead. And the shared quality is the point: these economics belong to the industry — proprietary content embedded in a professional's regulated workflow, sold by subscription — more than to any one member. WKL's advantage is real, but it is a good seat in a good industry, not a solo franchise.

Where the growth gap is

The economics say WKL belongs; the growth rates say it trails. On disclosed organic (underlying) revenue growth — the like-for-like measure that strips out currency and acquisitions — WKL grew 6% in 2025 [7], against RELX's 7% [8] and Thomson Reuters' 8% [9].

Sources: WKL 2025 organic 6% [10]; RELX underlying 7% [11]; Thomson Reuters organic 8% [12]; Intuit total revenue 16% [13].

Intuit's 16% [14] sits apart and should be read with care: Intuit is a consumer-and-small-business software and fintech platform (QuickBooks, TurboTax, Credit Karma), not a professional-information subscription house, and its growth is driven by payments, payroll, and consumer tax rather than the practitioner tools that overlap WKL. The tighter comparison is with RELX and Thomson Reuters, and there WKL is 100–200 basis points behind.

Legal, head to head

The gap concentrates where the three information rivals meet most directly. WKL's Legal & Regulatory division grew 5% organically in 2025 [15]. In the same year, RELX's Legal segment (LexisNexis) accelerated to 9% [16], and Thomson Reuters' Big Three segments — which include Legal Professionals — grew 9%, with Tax, Audit & Accounting guided to 11–13% [17].

Sources: WKL Legal & Regulatory 5% [18], Tax & Accounting 7% [19], Health 5% [20]; RELX Legal 9% [21] and STM 5% [22]; Thomson Reuters Big Three 9% and Tax midpoint 12% [23].

The picture is uneven, and that matters. In Health, WKL's Clinical Solutions (UpToDate) grew 7% and matched Elsevier's scientific-and-medical business at the divisional level [24]. In Tax & Accounting, WKL grew 7% with its cloud suite CCH Axcess up 19% organically [25] — respectable, though below the 11–13% Thomson Reuters expects from its own tax franchise. Legal is where WKL is most clearly outpaced: its two direct rivals grew their competing legal-research businesses nearly twice as fast. The 3% of Financial & Corporate Compliance [26] — a transaction-exposed business with no clean peer analog — pulls the group average down further.

AI posture across the cohort

The AI question established that content-plus-AI is table stakes, not a WKL edge. The peer record confirms it and adds a twist that cuts against the fear driving the derating. Every member runs the same play: RELX is embedding hundreds of GenAI workflow tools on its legal content and has stated flatly that licensing its content out is not on the table because "this is the centrepiece of our strategy" [27]. Thomson Reuters is scaling CoCounsel, its legal AI assistant, at double-digit growth [28]. Intuit has launched a "virtual team of AI agents" with AI-enabled human experts [29]. WKL's Expert AI is the same architecture — proprietary content, expert-in-the-loop validation, embedded delivery.

The twist: if generative AI were commoditizing professional content, the incumbents' content franchises would be decelerating. They are doing the opposite. RELX's Legal business accelerated to 9% as it rolled out GenAI tools [30], and its Risk division — where over 90% of revenue comes from embedded, machine-to-machine data feeds — grew 8% [31]. Thomson Reuters is guiding its Big Three faster in 2026 than 2025, citing AI-enabled adoption [32]. On the cohort's evidence so far, GenAI has been a tailwind for the strongest content businesses, not a solvent.

That same evidence, though, points to a mix distinction that the market can reasonably price. RELX's Risk revenue is 90% machine-to-machine — data piped into customers' own decision systems, structurally hard for a chatbot to disintermediate [33]. WKL's mix leans more toward human-facing reference and decision-support content — clinical, legal, and tax answers a professional reads — which is closer to what a general model appears able to approximate. The moat is the same in kind across the cohort; it may not be the same in degree.

The discount and what it tracks

WKL trades at ~10x trailing earnings. The cohort trades at roughly 20x (RELX, Intuit), 22x (Sage), 29x (Verisk), and 37x (Thomson Reuters).

Source: latest close ÷ reported diluted EPS for each name (WKL €57.62 ÷ €5.64 = 10.2x); approximate, trailing, from market prices and reported financials. See Ten Times Earnings for the forward-multiple and reverse-DCF treatment.

A discount of this size — WKL at roughly half the cheapest peer — is not explained by the economics in the first table, where WKL matches the cohort on margin and cash conversion. It is better explained by the second and third: WKL is the group's slowest organic grower, most visibly in Legal, and carries the mix most exposed to the substitution fear. The market's own scorecard agrees. Over 2023–2025, WKL's total shareholder return ranked near the bottom of this exact peer group — RELX returned roughly 40% and Thomson Reuters roughly 28% over the period while WKL's LTIP paid out zero on a bottom-quartile TSR rank [34] (Leadership Handover). The cohort compounded; WKL derated.

The moat read

The evidence supports a measured verdict: the cohort holds a wide, durable moat — proprietary content, regulated-workflow embedding, 90%-plus retention that has survived the cloud transition and, on rival evidence, is accelerating through the GenAI shift — and WKL is a genuine member of it, not a company being disrupted out of it. But WKL is a follower within the cohort rather than its pace-setter: durable, not differentiated. On current evidence the ~10x multiple is a peer-relative discount earned by slower growth, concentrated in Legal, and by a content mix the market judges more substitutable than RELX's machine-to-machine data or Intuit's transactional platform.

The strongest fact against reading WKL as a structural laggard is that the label is narrower than it looks. Its economics — margin, cash conversion, retention — are top-cohort, and two of its three shared arenas (Health at 7% in Clinical Solutions, Tax & Accounting at 7% with cloud up 19%) grow at or near the pace of their rivals [35], [36]. The gap is real but localized, not a whole-franchise decay.

What would change the read is measurable and dated: whether WKL's Legal and Tax organic growth converges toward the cohort's 9% as Expert AI adoption scales, versus staying 200–400 basis points behind while RELX and Thomson Reuters pull away. The first clean test is the H1-2026 print on 5 August 2026 — the earliest read on whether the reinvestment WKL is funding by halving its buyback is closing the growth gap that the discount is pricing.

---

Where AI can actually substitute the revenue

The fear behind Wolters Kluwer's derating is that generative AI lets a professional ask a chatbot instead of consulting proprietary content. Mapping the €6,125 million 2025 revenue base by how substitutable each part is, that exposure is narrower than the multiple implies: print — the one format a chatbot most cleanly replaces — is down to 4.75% of revenue, level with RELX's 4%. What WKL lacks is RELX's structural shield: a division that is ~90% machine-to-machine and therefore untouchable. Its content is more human-facing, and that is the honest reason it is discounted more.

Three disclosed cuts of the revenue base

Wolters Kluwer discloses its revenue three ways, each additive to the same €6,125 million. Together they bound the question of what AI could displace.

Source: FY2025 Annual Report — Group financial review (p.39) [1] and Note 6 Revenues (p.163) [2].

The first cut is by media format. Digital delivery is €5,250 million (86% of revenue), services €584 million (10%), and print €291 million — just 4.75% [3]. The second cut is by revenue recognition: €4,999 million (82%) is recognised over time — subscriptions that renew — and €1,126 million (18%) is recognised at a point in time, the transactional and one-off character [4]. The third cut is by product type: expert solutions — software plus advanced information solutions — are 59% of revenue, of which software solutions are about 45%; within software, cloud has reached 46% and grew 15% organically [5] [6].

Source: FY2025 Annual Report, Note 6 Revenues (p.163) [7]; FY2024 Annual Report, Note 6 (p.170, 2023 comparatives) [8].

Print is the sliver at the top of each bar, and it is shrinking in both euros and share — €327 million to €291 million over two years, 5.9% of revenue to 4.75% [9] [10]. Digital is not one thing, though, and the substitution question turns on splitting it.

A substitution ladder

Grouping the base by how easily a general-purpose model displaces it gives four tiers. The media-format split (software sits inside digital) anchors it; the software share is derived from the disclosed 45%, and the tiering is judgment, not a reported line.

Source: media-format and product-type figures from FY2025 Annual Report (p.39, p.163) [11] [12]; software share (45%) from FY2024 Annual Report (p.8) [13]; tiering derived.

Embedded software (~45%, ~€2,756 million). CCH Axcess, CCH Tagetik, OneSumX and TeamMate are systems of record wired into a firm's tax workflow, a bank's regulatory reporting, or an audit function [14]. A chatbot does not replace the platform that files the return or runs the Basel calculation; if anything it is embedded inside it. This tier grew: cloud software rose 15% organically to 46% of software revenue [15].

Services (~10%, €584 million). Almost all of this — €535 million — sits in Financial & Corporate Compliance, where Wolters Kluwer acts as registered agent, performs the legal-entity filing, and runs the lien search [16]. The value is the completed transaction, not an answer a model could generate. Alongside it, €447 million of transactional revenue in FCC and Legal & Regulatory is the same transaction-rail character [17]. It is cyclical — it moves with corporate and lending activity — but it is not content a chatbot substitutes.

Digital expert and reference content (~41%, ~€2,494 million). This is the contested tier: online information and decision-support that a professional consults — UpToDate for a clinician, legal and tax research, regulatory reference. It is where generative AI is both the threat and Wolters Kluwer's own product. The company's answer is to convert the content into the delivery channel: nearly 70% of digital revenue is now from AI-powered solutions, and the flagship products are wrapped in the expert-in-the-loop validation examined in Expert AI [18]. Renewal above 90% held through 2025 — reassuring, but a lagging indicator [19].

Print (4.75%, €291 million). The clearest substitution target — a medical or legal reference book a model can paraphrase — is already immaterial and declining. It concentrates almost entirely in two divisions.

Print is concentrated, and matches RELX

Print books and subscriptions live in Health (medical reference, €134 million) and Legal & Regulatory (legal reference, €118 million); together those two carry 87% of group print, while Tax & Accounting (€34 million), FCC (€5 million) and Corporate Performance and ESG (nil) are effectively paperless [20].

Source: FY2025 Annual Report, Note 6 Revenues — media format by segment (p.163) [21].

The "reference-content dinosaur" version of the bear case does not survive the number. At 4.75% of revenue, Wolters Kluwer's print exposure is essentially level with RELX's, which has spent 25 years running print from 64% of revenue down to 4% and now manages it separately as a runoff [22]. On the legacy-format axis, the two are the same business.

What RELX has that Wolters Kluwer does not

The genuine gap is one level up. RELX's Risk division — its highest-growth, highest-multiple engine — derives over 90% of revenue from machine-to-machine interactions: data and scores wired directly into customers' fraud, credit and compliance pipelines, with no human at a screen to disintermediate [23]. RELX management is explicit about why the division is AI-proof: the underlying data is "incredibly difficult to replicate" [24], and the "generative AI tools actually do not add significant value to those kinds of mathematical calculations" the business runs on [25].

Wolters Kluwer discloses no comparable machine-to-machine metric, and it has no single division built the way Risk is. Its embedded-software tier plays a similar defensive role, but its flagship products — the ones that carry the brand and the pricing power — are human-facing lookups: a clinician queries UpToDate, a lawyer runs a search. That is structurally more exposed to "the professional asks a model instead" than a data feed the customer never sees. The comparison is not print versus print; it is a human-in-the-loop content base versus a machine-in-the-loop data utility. The 90%-machine-to-machine crown jewel is precisely what Wolters Kluwer's revenue mix is missing, and it is a fair part of why the same GenAI wave that RELX's Risk business shrugs off is priced as a heavier threat here.

The read

On the primary record, Wolters Kluwer's revenue is less substitutable by generative AI than the derating implies. The cleanly displaceable bucket — print — is 4.75% of revenue, matches RELX, and is falling. Roughly 55% of revenue is embedded software, registered-agent services and transactional work that a chatbot does not replace. The exposure is real but concentrated in the ~41% human-facing content layer, and that layer renews above 90% and is being converted from threat into an AI delivery channel.

The strongest fact against this read is structural, not cyclical: Wolters Kluwer has no equivalent of RELX's 90%-machine-to-machine Risk division — no part of the base that is immune rather than defended [26]. Its most human-facing divisions, Health and Legal & Regulatory, are also its most print-heavy and, per Peer Benchmark, its slowest growers. What would change the read is renewal: if AI substitution is going to appear, it appears first as slipping retention or organic growth in Health and Legal & Regulatory. Those two divisions — not the group headline — are where this thesis is falsified or confirmed.

---

What to Watch

Eight chapters have established the pieces: a business still compounding, repriced to roughly ten times earnings on a generative-AI fear, discounting the slowest organic growth in its cohort. This chapter reconciles them. The disagreement between bull and bear is narrow and, unusually, testable: it turns on a handful of numbers that print on dated calendar days, the first of them being the half-year 2026 results on 5 August 2026. What follows separates what both sides accept from what only one side needs to be true, and names the thresholds that decide it.

The de-rating, decomposed

The starting fact both cases share is the size of the fall. Wolters Kluwer shares closed 2025 down 45% while the STOXX Europe 600 rose 21%, as the information-services and software sectors took a broad de-rating on AI-disruption fear and, in management's telling, "nearly all" of its stock-market peers fell too [1]. Market capitalisation fell from €38.3bn at the end of 2024 to €20.5bn a year later [2].

Source: FY2025 Annual Report — market capitalisation €20.5bn (2024: €38.3bn) [2]; five-year share return +28% vs STOXX Europe 600 +54% [1].

That framing matters because it splits the de-rating in two. Part of it was a sector event — a multiple compression applied to the whole information-services group on generalised AI fear, not on any company-specific stumble. But the peers did not stay compressed: RELX, Thomson Reuters and Verisk now trade at roughly 16x, 19x and 24x forward earnings, while Wolters Kluwer sits near 10x on FY2025 adjusted EPS of €5.29 [3]. The residual gap — WKL at ten times against a cohort at sixteen-plus — is company-specific, and the competitive record (Peer Benchmark) traces it to a real, localised growth deficit: WKL grew 6% organically in 2025 against RELX's 7% and Thomson Reuters' 8%, and in Legal, where the three meet head-to-head, WKL's Legal & Regulatory grew 5% [4] against RELX's 9% [5]. The sector-fear component is shared and, on the peers' recovery, largely reversed; the earned component is the growth gap, and it is the part the next few prints will confirm or close.

Where bull and bear diverge

Set against each other, the two cases agree on almost every fact in the report. They part on what each fact implies. The rows below are the load-bearing disagreements, each built on a shared number rather than a sentiment.

Sources: organic growth, margin and adjusted EPS, FY2025 Annual Report [3]; recurring revenue 83% and renewal above 90% [6]; net debt €4,024m at 2.0x and equity €798m [7]; 2026 buyback of up to €500m [8] and product-development step-up to 12–13% [9]. Forward peer multiples are market data, early July 2026.

Two of these deserve to be stated straight, because they are the strongest facts each side holds. For the bear, the compounding formula is already bending on its own terms, before AI proves anything: 2026 guidance is for high-single-digit adjusted-EPS growth, not the double-digit the decade delivered, and the buyback that supplied roughly a third of 2025's EPS growth has been cut to up to €500m from about €1bn while product-development spend rises to 12–13% of revenue [9]. That is a real near-term deceleration, chosen rather than forced. For the bull, the reinvestment is the point, not a concession: management still guides the adjusted operating margin up toward 28% in 2026 while absorbing the higher spend, and adjusted free cash flow of €1,300–1,350m barely below the €1,348m just delivered [10]. The lever being withdrawn is buybacks; the levers being defended are margin and cash. Which reading is right is a matter of outcomes, not framing, and the outcomes are dated.

The outcome brackets

Because near-term earnings are well-anchored — high-single-digit EPS guidance on 83% recurring revenue renewing above 90% [6] — the spread of outcomes over two to three years is governed mostly by the exit multiple, the same conclusion the valuation work reached (Ten Times Earnings). What this synthesis adds is the link from each multiple to the observable that would justify it.

Source: illustrative scenarios by the author, extending the grid in Ten Times Earnings. EPS anchored on FY2026–27 consensus (~€5.6/€6.2/€6.8) flexed for organic-growth outcomes; exit multiples span from below today's ~10x to a discount to RELX's ~16x. FY2025 adjusted FCF €1,348m and adjusted EPS €5.29 per the FY2025 Annual Report [3] [11]; current price ~€58 is market data.

The columns show where the leverage sits. Move the exit multiple from 9x to 13x to 17x and the price runs from about €50 to €81 to €116 — a swing far larger than the earnings flex within any single row. The bear world is not a collapse; it is organic growth stalling below 5% and the multiple staying near where it is, which leaves the shares roughly flat to modestly lower. The base case needs only that guidance holds and the multiple normalises part-way toward a still-discounted 13x, which delivers the bulk of the ~€100 consensus target without an earnings inflection. The bull case is the one that requires something new: Legal and Tax organic growth converging toward the cohort's 9% as Expert AI monetisation scales. Each of those is observable within a few quarters.

What would change the read

The watch-list below is the practical output of the report: dated, falsifiable items, each with the line it appears in and the threshold that would move the read. It is ordered by decision value, and the near-term entries cluster on one date.

Sources: half-year 2026 results dated 5 August 2026 per the FY2025 Annual Report financial calendar [12]; Q1 2026 organic growth 5% and recurring 7%, with more than half of U.S. Enterprise customers signed up to adopt UpToDate Expert AI [13]; FY2026 divisional guidance (FCC and Legal & Regulatory growth expected ahead of prior year) [14]; margin, RELX Risk and leverage anchors per prior chapters.

The first quarter under Stacey Caywood is a partial read, and it points sideways rather than up: Q1 2026 organic growth held at 5%, level with the prior year, recurring revenue sustained 7%, and full-year guidance was reiterated unchanged, with more than half of U.S. Enterprise customers now signed up to adopt UpToDate Expert AI [13]. Management expects Financial & Corporate Compliance and Legal & Regulatory organic growth to run ahead of the prior year, with momentum weighted to the second half [14]. That is consistent with the base case and, so far, neither confirms the bull's acceleration nor the bear's erosion.

Where the evidence lands, then, is a two-sided position with a short fuse. The bear owns two facts that are already true — the slowest organic growth in the cohort and an EPS algorithm being re-weighted away from buybacks — and one that is not yet visible, AI substitution in the human-facing content that renewal above 90% has so far masked [6]. The bull owns a business that still converts nearly all its earnings to cash at a margin guided higher, priced at a multiple its own recovering peers left behind, where a partial re-rating on unchanged earnings is the larger part of the return. The variable that separates them is not the multiple in isolation but the growth that would earn it, and unusually for a franchise-durability debate, it resolves on scheduled dates — beginning 5 August 2026 [12]. The watch-list is what to read when it does.